Status: Private

 

ADARx is developing a modality agnostic RNA targeting platform, including oligonucleotides for inhibition, degradation and editing, together with novel oligonucleotide delivery technologies. They are currently focused on diseases in three therapeutic areas: genetic diseases, cardiometabolic diseases, and central nervous system (CNS) diseases. With RNA as the target of their drug discovery, they are able to work on a wide range of diseases and will continue to add additional disease targets to their pipeline in areas of unmet medical need.

 

To learn more, please visit: www.adarx.com